Ccne1-amplified Solid Tumors

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-17
Clinical Trial Update: Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]
Novartis' ECI830 is being studied as a single agent or in combination in adults with advanced HR+/HER2- breast cancer and other advanced sol…